Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
Go back to Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026| Beam Inc. (NASDAQ: BEAM) | Delayed: 24.95 +0.28 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.67 | 52 Week High | $83.60 | |||
| Open | $24.92 | 52 Week Low | $82.96 | |||
| Day High | $25.18 | P/E | 11.14 | |||
| Day Low | $24.26 | EPS | $2.24 | |||
| Volume | 2,288,143 | |||||
